Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching AnalysisTakashi Niizeki, Yasuhito Tanaka|Targeted Oncology|2022Cited by 41